Solventum Corporation $SOLV Holdings Lifted by Lone Peak Global Investors LLC

Lone Peak Global Investors LLC increased its stake in shares of Solventum Corporation (NYSE:SOLV) by 38.5% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 433,128 shares of the company’s stock after acquiring an additional 120,352 shares during the quarter. Solventum comprises about 4.6% of Lone Peak Global Investors LLC’s portfolio, making the stock its 3rd largest holding. Lone Peak Global Investors LLC owned approximately 0.25% of Solventum worth $33,416,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of SOLV. Diamond Hill Capital Management LLC Investment Advisor bought a new position in Solventum during the second quarter valued at $150,066,000. SG Americas Securities LLC grew its position in Solventum by 38.4% in the 1st quarter. SG Americas Securities LLC now owns 129,663 shares of the company’s stock valued at $8,467,000 after acquiring an additional 35,982 shares during the last quarter. First Trust Advisors LP increased its stake in Solventum by 57.4% in the first quarter. First Trust Advisors LP now owns 334,441 shares of the company’s stock worth $21,839,000 after purchasing an additional 121,989 shares during the period. Bank of America Corp DE lifted its position in shares of Solventum by 0.6% during the first quarter. Bank of America Corp DE now owns 1,432,780 shares of the company’s stock worth $93,561,000 after purchasing an additional 9,083 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in shares of Solventum during the second quarter worth $61,460,000.

Solventum Trading Down 0.2%

SOLV opened at $90.86 on Wednesday. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 1.00. The firm has a market cap of $15.47 billion, a price-to-earnings ratio of 11.11, a PEG ratio of 1.17 and a beta of 0.60. Solventum Corporation has a 12 month low of $62.38 and a 12 month high of $94.16. The stock has a fifty day moving average price of $83.14 and a 200-day moving average price of $75.67.

Solventum (NYSE:SOLV) last posted its earnings results on Wednesday, August 5th. The company reported $2.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.91 by $0.64. Solventum had a return on equity of 25.09% and a net margin of 17.26%.The company had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.15 billion. During the same quarter in the previous year, the firm earned $1.69 earnings per share. The firm’s quarterly revenue was up 2.2% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. As a group, equities research analysts anticipate that Solventum Corporation will post 7.22 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on SOLV shares. BMO Capital Markets started coverage on shares of Solventum in a report on Wednesday, July 8th. They set a “market perform” rating and a $81.00 price objective for the company. Wedbush lifted their price target on shares of Solventum from $94.00 to $101.00 and gave the company an “outperform” rating in a research note on Thursday, August 6th. Mizuho set a $113.00 price target on Solventum in a report on Thursday, August 6th. Weiss Ratings raised Solventum from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, August 18th. Finally, Wells Fargo & Company decreased their target price on Solventum from $83.00 to $70.00 and set an “equal weight” rating for the company in a research report on Wednesday, May 6th. Eight analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $91.64.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.